PCJ.F ABEONA THERAPEUT. DL-01

Healthcare Biotechnology Frankfurt Exchange
2.03 EUR
Close of Nov 12, 2026
2.03 7.08
Market cap
EUR 125M
P/E
-
P/B
1.18x
ROE
-44.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PCJ.F undervalued?

Graham number

The Graham number of ABEONA THERAPEUT. DL-01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ABEONA THERAPEUT. DL-01 fundamental analysis

No fundamental analysis for ABEONA THERAPEUT. DL-01 yet.

ABEONA THERAPEUT. DL-01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ABEONA THERAPEUT. DL-01

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition,…

Full company profile